Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jan 20, 2022 8:38pm

147 Views

Post# 34340670

RE:RE:New Presentation is up

That was my thought, the slides just represent the last public statement.

As we all know they are sitting on a China cancer deal, NASH partner who's paying for the Ph3, two CRs in the cancer trial and exploding Egrifta sales. Just waiting for for the right moment to tell us. (I might be wrong!)

LouisW wrote:
I don't think a normal company will update clinical progress through showing slide instead of releasing a PR. But I am also wondering why they took so long to revise a slide if they just revised the date

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing